RxDoctor Payments DataLook up a doctor →

Raghava Induru, MD

Medical Oncology · Albemarle, NCNPI 1063608388

Payments from drug & device makers

$709,567in general payments, 2019–2025

Across 521 payments — averaging $1361.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$219K
  • AstraZeneca$155K
  • Regeneron Healthcare Solutions, Inc.$154K
  • Novartis$85K
  • Sanofi$31K
  • Daiichi Sankyo Inc.$27K
  • plus $39K from 7 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$709,567 in reported general payments places this provider in the 80th percentile of 170 medical oncology providers in North Carolina.

See all medical oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,180
Medicare patients
283
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Albemarle

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →